By discovering and developing innovative biological MSC stem cells therapies and make them accessible to patients throughout the world.
By keeping our patients’ and customers’ safety and well-being at the core of everything we do.
By partnering with leading hospitals, healthcare professionals and academia.
Our business in numbers
20B
ASCs from 100 ml of adipose tissue over 2 weeks 3D cell culturing
80%
Patent coverage of global market until 2034
80%
More volume (fat retention) compared to conventional fat grafting published in The Lancet
67
Real World Patients treated
Science
Our platform
Our core science is focused on producing and expanding very high quantities of potent autologous MSCs. Despite the many opportunities in cell therapy, the focus of StemMedical is clear and divided into two main strategic segments.
covers the cosmetic application of the technology. Stemform cultured stem cell fat transfer treatment offers women a natural and effective breast augmentation as an alternative to artificial implants.
Leading investors discuss the global investment landscape and shifts in public and private finance, as well as what they expect 2023 and onwards to hold.
Stamcelleselskab har sikret sig halvdelen af ønsket kapital
Stamcellefirmaet Stemmedicalindledte i sommeren 2022 en pengerunde, der skulle sikre selskabet i alt 15 mio. euro, svarende til næsten 112 mio. kr., og nu er halvdelen af pengene i hus, oplyser Stemmedical til Børsen.
%20(2).png?width=1308&height=1257&name=S_DSC0808_20171117141501_edit%20(1)%20(2).png)
